Case Report

Toxic epidermal necrolysis and concurrent granulomatosis with polyangiitis (Wegener’s granulomatosis). Management of a rare case and review of the literature

Stratos S Sofos, Jordan Ewing, Laura C Hughes and Malcolm I James

Abstract

Toxic epidermal necrolysis (TEN) is a rare, acute life-threatening mucocutaneous disorder that is characterised by epidermal loss/exfoliation exceeding 30% total body surface area (TBSA) and is on a spectrum that includes erythema multiforme and Stevens–Johnson syndrome (SJS). It is estimated that 80% of TEN cases are related to medication reactions; the association based on the recognition that TEN usually develops 1–3 weeks following administration of the suspect drug. It is agreed that primary treatment consists of prompt withdrawal of causative drugs and transfer to a regional burn unit. Transfer to a burn unit, no more than 7 days after onset of symptoms, has been acknowledged as reducing the risk of infections, hospital length of stay and infection-related mortality. Due to the uncertainty surrounding TEN pathogenesis, several different modalities have been proposed for the treatment of TEN, including high-dose intravenous immunoglobulins, plasmapheresis, cyclophosphamide, cyclosporine and systemic steroids; however, these therapies are relatively ineffective. The use of systemic corticosteroids for treatment of TEN has in particular been deemed controversial due to associations with increased infections leading to greater length of hospital stay and increased mortality.

Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s granulomatosis, is a rare relapsing-remitting disorder of unknown aetiology, characterised by granulomatosis inflammation and necrotising vasculitis predominantly affecting small- to medium-sized vessels. While a 5-year survival rate of 75–83% is now realised, relapse and associated morbidity is of concern.

The established treatment for GPA follows the recommendations of the French National Authority for Health (HAS) for systematic necrotising vasculitis. With induction treatment, it is recommended that GPA be treated with a combination of systemic corticosteroids and immunosuppressants.

A review of the literature failed to identify any previous case where both of these conditions coincide. Our search was conducted through databases which included MEDLINE, PubMed, Scopus, AMED, CINAHL and EMBASE, using keywords: toxic epidermal necrolysis, Wegener’s granulomatosis, granulomatosis with polyangiitis. We submit the rare case of a 22-year-old woman who presented to our regional burn unit with both GPA and TEN, and we discuss the presentation, investigation and multidisciplinary management of the patient, as well as reviewing the literature regarding these two conditions.

Keywords

Toxic epidermal necrolysis, concurrent, granulomatosis with polyangiitis, Wegener’s granulomatosis, burns unit, treatment

Whiston Hospital, Prescot, UK

Corresponding author:
Stratos S Sofos, Whiston Hospital, Prescot L35 1DR, UK.
Email: Tsofos@hotmail.com

Creative Commons Non Commercial CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Lay Summary

Toxic epidermal necrolysis is a potentially fatal condition where there is a large area of skin exfoliated after the body’s reaction to a particular medication. Its treatment is largely by stopping the medication that is thought to have caused this reaction and also by regular dressings, thus keeping the area clean from any infection. Granulomatosis with polyangiitis, also known as Wegener’s granulomatosis, is another potentially fatal condition. Its treatment is very specific; however, this treatment may be harmful to a patient with toxic epidermal necrolysis. We describe the management of a patient who presented with both conditions, which is an extremely rare event. We describe the diagnosis and treatment during the patient’s inpatient stay at a regional burns unit. From this case report we have shown insight into the multidisciplinary management needed to manage such a complex patient, who made a full recovery.

Case report

A 22-year-old woman was referred by the critical care team of a district general hospital (DGH) to our regional burns unit with 100% TBSA involvement following toxic epidermal necrolysis (TEN) on the background of GPA. The patient initially presented to the DGH with a fever, shortness of breath and feeling generally unwell. A chest X-ray demonstrated multiple opacities and on computerised tomography (CT) of the chest and abdomen, she was found to have multiple cavitations, a pulmonary embolism and a femoral thrombosis. Granulomatosis with polyangiitis (GPA) was confirmed and the patient was commenced on warfarin, rituximab, methylprednisolone, Immunoglobulins (IgG) and fluconazole, to which she responded well. As part of this regime she had a second and third infusion of rituximab and prophylactic co-trimoxazole.

Three days following co-trimoxazole, she presented back to the DGH with angioedema and had developed a rash with an estimated 90% total body surface area (TBSA), involving the oral and ophthalmic mucosa. Fluconazole and co-trimoxazole were immediately stopped and the steroids increased with the initial suspicion of Stevens–Johnson syndrome (SJS). The patient deteriorated, progressing to 100% TBSA, and required significant support from the critical care team. TEN was suspected and subsequently confirmed by skin biopsy. She had an initial SCORTEN (SCORe of Toxic Epidermal Necrosis) score of 3, predicting a 35.3% mortality risk, and was accordingly referred and transferred to our specialist burns centre for management of her extensive wounds. Figure 1a and b show the large extent of the TBSA involved in this patient.

Piperacillin/Tazobactam (Tazocin) and Vancomycin antibiotics were commenced following sputum and wound swab sensitivities. One week following admission, prednisolone was reduced to 40 mg daily. After 10 days of treatment, there was good re-epithelisation of the skin. The patient was discharged at 3 weeks following a period of physiotherapy.

Discussion

GPA is a serious disease, with a fatal outcome in the absence of treatment. Fortunately, with therapeutic approaches that are increasingly standardised and the emergence of new biotherapies, 90% of patients go into remission, and the survival rate is approximately 75–83% at 5 years. The current treatment is based on a first phase, known as the induction phase, which aims to put
the disease into remission, and lasts about 3–6 months according to the clinical response. A second phase, known as the maintenance phase, must then consolidate the remission and limit the risk of relapse and generally lasts 12–24 months. The intensity of the initial therapeutic approach must be adjusted for each patient and for the type and seriousness of GPA in order to avoid two pitfalls: excessive treatment associated with a significant risk of side effects, or insufficient treatment with a risk of failure or early relapse. With induction treatment, it is recommended that GPA be treated with a systemic corticosteroid and immunosuppressant combination. Oral prednisone is recommended at a daily starting dose of 1 mg/kg. For severe or refractory forms, oral corticosteroid therapy is preceded by an intravenous bolus of methylprednisolone at a dosage of 7.5 mg to first flare up or relapse (results under publication). Rituximab has a lower risk of relapse compared to azathioprine at 28 and 44 months after the start of the maintenance treatment (rate of major relapses at 44 months: 18.2% in the rituximab arm vs. 51.9% in the azathioprine arm). Treatment with co-trimoxazole (sulfamethoxazole/trimethoprim at a dose of 400 mg/80 mg) per day is systematically given for the prevention of relapse of Pneumocystis jirovecii infections. The treatment regimens are increasingly adapted to the expression of the disease and to its course; relapses remain frequent, however, and the maintenance treatment methods warrant better standardization.1

Glucocorticosteroids are prescribed in conjunction with induction therapy immunosuppressants and are not prescribed as monotherapy to induce clinical remission in GPA. Corticosteroids are prescribed at high doses while the disease is active then gradually tapered to the lowest dose of corticosteroid required to maintain remission with concomitant immunosuppressive drugs.

Although guidelines have been proposed regarding the treatment of TEN,2,3 its rarity hinders the establishment of treatment based on large prospective studies, and subsequently management standards have not been widely accepted.4 It is, however, agreed that primary treatment consists of prompt withdrawal of causative drugs5 and transfer to a regional burn unit. Transfer to a burn unit, no more than 7 days after onset of symptoms, has been acknowledged as reducing the risk of infections, hospital length of stay and infection-related mortality.6-9

TEN management focuses on resuscitative, symptomatic and supportive strategies, and comprises fluid resuscitation and electrolyte replacement, nutritional support, as well as suitable and targeted wound care.7,10 With sepsis being recognised as the leading cause of mortality in the TEN population,5,11 increased attentiveness towards skin care is warranted and includes prevention, early detection and treatment of infection10 achieved by frequent skin, blood and urine cultures.11 Emphasis must also be placed on the role of analgesia, deep vein thrombosis/pulmonary embolism and erosive gastric ulcer prophylaxis, and regular physiotherapy.11

Due to the uncertainty surrounding TEN pathogenesis, several different modalities have been proposed for the treatment of TEN, including high-dose intravenous immunoglobulins, plasmapheresis, cyclophosphamide, cyclosporine and systemic steroids; however, these therapies are relatively ineffective.13,14 The use of systemic corticosteroids for treatment of TEN has in particular been deemed controversial due to associations with increased infections leading to greater length of hospital stay and increased mortality.15-20 In a study by Halebian et al.,15 15 consecutive patients with TEN or SJS managed without corticosteroids after transfer to the burn centre (group 2) were compared to a previous consecutive group of 15 patients who received high doses of these drugs (group 1). Group 2 had a 66% survival, which was a significant improvement compared to the 33% survival in group 1 (P = 0.057). In group 1, mortality was associated with loss of more than 50% TBSA skin loss. In group 2, mortality was related to advanced age and associated diseases. Non-steroid (group 2) management was associated with a decreased incidence of ulceration of gastrointestinal columnar epithelium, Candida sepsis, and an increased survival after septic complications.

Conclusion
TEN with GPA are both life-threatening illnesses. Treatment for GPA is well established and steroid use is part of this treatment in both the induction as well as the maintenance phase stages. Robust evidence for or against the use of steroids in the treatment of TEN is unavailable, but available published literature suggests that they can be harmful. We present an exceptionally rare case where both of these diseases occurred concurrently and raise awareness to the controversial role of steroid use in TENs. We also emphasise the importance of a multidisciplinary team approach for the management of such a complex case.
Declaration of conflicting interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval
The authors confirm that the necessary written, informed consent was obtained from patients for this article.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References
1. Mockenhaupt M, Vibound C, Dumant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR study. J Invest Dermatol 2008; 128(1): 35–44.
2. Viard I, Wehrli P and Bullani R. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282(5388): 490–493.
3. Downey A, Jackson C, Harun N, et al. Toxic epidermal necrolysis: review of pathogenesis and management. J Am Acad Dermatol 2012; 66(6): 995–1003.
4. Paul C, Wolkenstein P, Adle H, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996; 134(1): 710–714.
5. La Grenade L, Lee L, Weaver J, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective OX2 inhibitors. Drug Safety 2005; 28(10): 917–924.
6. Oplatek A, Brown K, Sen S, et al. Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res 2006; 27(1): 26–33.
7. Lissia M, Mulas P, Bulla A, et al. Toxic epidermal necrolysis (Lyell’s disease). Burns 2010; 36(1): 152–163.
8. Gerull R, Nelle M and Schaible T. Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review. Crit Care Med 2011; 39(6): 1351–1352.
9. Chave TA, Mortimer NJ, Sladden MJ, et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005; 153(2): 241–253.
10. Wehrli P, Viard I, Bullani R, et al. Death receptors in cutaneous biology and disease. J Invest Dermatol 2000; 115(2): 141–148.
11. Rzany B, Correia O, Kelly JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study On Severe Cutaneous Adverse Reactions. Lancet 1999; 353(9171): 2190–2194.
12. Endorf FW, Cancio LC and Gibran NS. Toxic epidermal necrolysis clinical guidelines. J Burn Care Res 2008; 29(5): 706–712.
13. French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Allergol Int 2006; 55(1): 9–16.
14. Valevici-Allanore L, Sassolas B and Roujeau JC. Drug-induced skin, nail and hair disorders. Drug Safety 2007; 30(11): 1011–1030.
15. Mahar PD, Wasiak J, Hii B, et al. A systematic review of the management and outcome of toxic epidermal necrolysis in burns centres. Burns 2014; 40(7): 1245–1254.
16. Dolan P, Flowers FP, Araujo OE, et al. Toxic epidermal necrolysis. J Emerg Med 1989; 7(1): 65–69.
17. Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges 2009; 7(2): 142–160.
18. Ruiz-Maldonado R. Acute disseminated epidermal necrosis types 1, 2 and 3: a study of sixty cases. J Am Acad Dermatol 1985; 13(4): 623–625.
19. Becker D. Toxic epidermal necrolysis. Lancet 1998; 351(9113): 1417–1419.
20. Stella M, Clemente A, Boller D, et al. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns 2007; 33(4): 452–459.
21. Bastuji-Garin S, Rzany B, Shear NH, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1995; 130(1): 92–96.
22. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333(24): 1600–1607.
23. Abood GJ, Nickoloff BJ and Gamelli RL. Treatment strategies in toxic epidermal necrolysis syndrome: where are we at? J Burn Care Res 2008; 29(1): 269–276.
24. Mofid MZ, Costarangos C, Bernstein B, et al. Drug-induced linear immunoglobulin A bullous disease that clinically mimics toxic epidermal necrolysis. J Burn Care Rehabil 2000; 21(3): 246–247.
25. Ducic I, Shalom A, Rising W, et al. Outcome of patients with toxic epidermal necrolysis syndrome revisited. Plast Reconstr Surg 2002; 110(3): 768–773.
26. Dalli RL, Kumar R, Kennedy P, et al. Toxic epidermal necrolysis/Stevens-Johnson syndrome: current trends in management. ANZ J Surg 2007; 77(8): 671–676.
27. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115(2): 149–153.
28. Cartotto R, Mayich M, Nickerson D, et al. SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center. J Burn Care Res 2008; 29(1): 141–146.
29. Schulz JT, Sheridan RL, Ryan CM, et al. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2000; 21(3): 199–204.
30. Hii BW, Mahar PD, Wasiak J, et al. Hospital management and clinical factors associated with ophthalmic involvement in toxic epidermal necrolysis. Burns 2014; 40(5): 903–908.
31. Fritsch P and Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol 2000; 1(6): 349–360.
32. Pasquier P and Piéard GE. New insights in toxic epidermal necrolysis (Lyell’s syndrome): clinical considerations, pathobiology and targeted treatments revisited. Drug Safety 2010; 33(3): 189–212.
33. Palmieri TI, Greenhalgh DG, Saffle JR, et al. A multicentre review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 2002; 23(2): 87–96.
34. Zakrzewski JL, Lentini G, Such U, et al. Toxic epidermal necrolysis: differential diagnosis of an epidermolytic dermatopathy in a hematopoietic stem cell transplant recipient. Bone Marrow Transplant 2002; 30(5): 331–333.
35. Fromowitz J, Ramos-Caro F, Flowers F, et al. Practical guidelines for management of toxic epidermal necrolysis and Stevens-Johnson syndrome. Int J Dermatol 2007; 46(10): 1092–1094.
36. Endorf FW, Cancio LC and Gibran NS. Toxic epidermal necrolysis clinical guidelines. J Burn Care Res 2008; 29(5): 706–712.
37. Garcia-Doval I, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136(3): 323–327.

38. McGee T and Munster A. Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. Plast Reconstr Surg 1998; 102(4): 1018–22.

39. Gerdts B, Vloemans A and Kreis R. Toxic epidermal necrolysis; 15 years’ experience in a Dutch burns centre. J Eur Acad Dermatol Venereol 2007; 21(6): 781–788.

40. Widgerow AD. Toxic epidermal necrolysis – management issues and treatment options. Int J Burns Trauma 2011; 1(1): 42–50.

41. Harr T and French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis 2010; 5: 39.

42. Schwartz RA, McDonough PH and Lee BW. Toxic epidermal necrolysis. Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol 2013; 69(2): 187.e1–16.

43. Halebian PH, Corder VJ, Malden MR, et al. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204(5): 119–127.

44. Heimbach DM, Engrav LH, Marvin JA, et al. Toxic epidermal necrolysis. JAMA 1987; 257(16): 2171–2175.

45. Kelemen JJ 3rd, Cioffi WG, McManus WF, et al. Burn center care for patients with toxic epidermal necrolysis. J Am Coll Surg 1995; 180(3): 273–278.

46. Engelhardt SL, Schurr MJ and Helgerson RB. Toxic epidermal necrolysis: an analysis of referral patterns and steroid usage. J Burn Care Rehabil 1997; 18(6): 520–524.

47. Pereira FA, Mudgil AV and Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol 2007; 56(2): 181–200.

48. Kardaun SH and Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 2007; 87(2): 144–148.

49. Jennette JC and Falk RJ. Small-vessel vasculitis. N Engl J Med 1997; 337(21): 1512–1523.

50. Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65(1): 1–11.

51. Wowrodt A, Haubitz M, Haller H, et al. Wegener’s granulomatosis. Lancet 2006; 367(9519): 1362–1366.

52. Watts RA, Al-Taiar A, Scott Dgi, et al. Prevalence and incidence of Wegener’s granulomatosis in the UK General Practice Research Database. Arthritis Rheum 2009; 61(10): 1412–1416.

53. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, et al. Stable incidence of primary systemic vasculitides over five years: Results from the German vasculitis register. Arthritis Rheum 2005; 53(1): 93–9.

54. Fujimoto S, Watts RA, Kobayashi S, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the UK. Rheumatology 2011; 50(10): 1916–1920.

55. Katsuyama T, Sada KE and Makino H. Current concept and epidemiology of systemic vasculitides. Allergol Int 2014; 63(4): 505–513.

56. Mohammad AJ, Jacobsson LT, Westman KW, et al. Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology 2009; 48(12): 1560–1565.

57. Luqmani R, Suppiah R, Edwards CJ, et al. Mortality in Wegener’s granulomatosis: a bimodal pattern. Rheumatology 2011; 50(4): 697–702.

58. Walsh M, Flossmann O, Berden A, et al.; European Vasculitis Study Group. Risk factors for relapse of anti-neutrophil cytoplasmic anti-body-associated vasculitis. Arthritis Rheum 2012; 64(2): 542–548.